Amgen's strong financials and guidance beat forecasts

3 February 2017
2019_biotech_test_vial_discovery_big

Reporting fourth-quarter financial results late on Thursday, US biotech major Amgen (Nasdaq: AMGN) pleased investors, with its shares rising as much as 3.7% $165.55 in after-hours trading.

The company reported non- generally accepted accounting principles (GAAP) earnings per share of $2.89, a year on year rise of 11% in earnings per share (EPS) versus consensus estimates of $2.79. Non-GAAP operating income increased 2%1 in the fourth quarter to $2.9 billion. Total revenue for the quarter rose 8%coming in at $5.97 billion in revenue, versus consensus estimates and $5.54 billion.

For the full year, total revenues increased 6 to $23.0 billion, with 5 product sales growth. Non-GAAP EPS increased 12% to $11.65, driven by higher revenues and higher operating margins. Non-GAAP operating income increased 14% for the full year to $11.4 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology